2015-11-15T17:05:04-06:00 2014-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 8TH FLOOR MCLEAN VA 22102 990 2014-01-01 522044704 AERAS % DONNA D'AMATO AERA 3015472900 1405 RESEARCH BLVD SUITE 300 ROCKVILLE MD 20850 Dan Reznikov CFO 3015472892 2015-11-13 true Jeffrey J Schragg P00234543 7038930600 2014 2016-04-25 22:37:26Z JACQUELINE LUCAS 1405 RESEARCH BLVD ROCKVILLE MD 20850 52148139 false X WWW.AERAS.ORG X 1997 DC DEDICATED TO THE DEVELOPMENT OF EFFECTIVE TUBERCULOSIS (TB) VACCINES & BIOLOGICS TO PREVENT TB ACROSS ALL AGE GROUPS IN AN AFFORDABLE & SUSTAINABLE MANNER. 11 10 165 10 2521169 0 53525841 49605233 1393354 2555918 116369 87258 -41122 -143455 54994442 52104954 1934033 500000 0 0 19003953 19875713 0 0 0 27328534 37683490 48266520 58059203 6727922 -5954249 51799335 45384143 8949247 8493078 42850088 36891065 X AERAS IS A NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATION DEDICATED TO THE DEVELOPMENT OF EFFECTIVE TUBERCULOSIS (TB) VACCINES AND BIOLOGICS TO PREVENT TB ACROSS ALL AGE GROUPS IN AN AFFORDABLE AND SUSTAINABLE MANNER. AERAS UTILIZES ITS BROAD CAPABILITIES AND TECHNOLOGIES IN COLLABORATION WITH NUMEROUS PARTNERS AND STAKEHOLDERS TO SUPPORT THE DEVELOPMENT OF VACCINES AND OTHER BIOPHARMACEUTICALS TO ADDRESS TB AND OTHER SIGNIFICANT PUBLIC HEALTH NEEDS OF UNDERSERVED POPULATIONS. IN THE PURSUIT OF OUR MISSION, WE ARE GUIDED BY OUR CORE VALUES. THESE CORE VALUES EXPRESS OUR ASPIRATIONS AND THE BEHAVIORS WE WANT TO EXHIBIT AND MODEL. THEY SHAPE THE CULTURE AND CHARACTER OF AERAS AND INFORM ALL OF OUR DECISIONS AND ACTIONS. false false 11631336 Preclinical - Aeras develops and assesses a range of vaccine platforms and variations, and explores novel approaches to enhance the effectiveness of new TB vaccines in effective prime-boost regimens. Aeras evaluates TB vaccine candidates to determine whether they have the characteristics needed to move forward to the next phase of development. Key elements include evaluation of safety, immunogenicity and the protection the candidates provide in animal models. An independent panel of vaccine experts evaluates all relevant preclinical data before a candidate is approved for entry into Phase I trials. Aeras also supports the assessment of novel assays that could be implemented at the clinical stage of development to drastically reduce the time and cost of developing new vaccines against tuberculosis. 19492123 Clinical - Aeras and its research partners have transformed the TB vaccine clinical landscape. Six vaccine candidates are undergoing testing in clinical trials in Kenya, Senegal, South Africa, the United Kingdom, and the United States with support from Aeras for protocol development, safety monitoring, regulatory and immunology. We also design and conduct epidemiology studies to estimate TB prevalence and/or incidence under real-world trial conditions to inform ongoing studies and to assess the feasibility of conducting large-scale clinical trials in TB at additional research sites in TB endemic countries, including China. 15031350 2555917 Tech Operations - Vaccine manufacturing facility located at Aeras headquarters designed to manufacture internally developed vaccine candidates based on a range of technology platforms capabilities in bacterial, viral and protein vaccines. Aeras has cGMP-compliant, end-to-end equipment and operating capabilities that meet both US FDA and European EMEA standards. Process development and manufacturing capabilities support translation from research to clinical development, including manufacturing of clinical trial materials for Aeras-sponsored trials. The Facility is also used in collaboration with external vaccine partners and contract product development services clients. 5845506 52000315 true true false false false false false false false false true false false false true true false true false true true true false false false false false false false true false false false false false false false false false false false false false true true true false false true X 67 0 165 true true true true SF HK CH false false false false false false false false X 11 10 false false false false false false false true true false false true true true true true true true true false MD X X DONNA D'AMATO 3015472923 1405 RESEARCH BLVD STE 300 ROCKVILLE MD 20850 X Lota Zoth Chairman 1.0 0.0 X 0 0 0 Barry Bloom Director 1.0 0.0 X 0 0 0 James Connolly Director 1.0 0.0 X 0 0 0 Marja Esveld Director 1.0 0.0 X 0 0 0 Peter Hutt Director 1.0 0.0 X 0 0 0 Marian Jacobs Director 1.0 0.0 X 0 0 0 Michel Kazatchkine Director 1.0 0.0 X 0 0 0 Wayne Pisano Director 1.0 0.0 X 0 0 0 Regina Rabinovich Director 1.0 0.0 X 0 0 0 Gerd Zettlmeissl Director 1.0 0.0 X 0 0 0 Thomas Evans President & CEO 40.0 0.0 X X 488943 0 35672 ANN GINSBERG CMO 40.0 0.0 X 346087 0 21078 JACQUELINE SHEA LUCAS COO 40.0 0.0 X 228873 0 17847 WENDY PENRY CHRO 40.0 0.0 X 210147 0 31220 DANIEL REZNIKOV CFO FROM 5/1/14 40.0 0.0 X 154387 0 8763 GERARD FLEURY CFO THRU 1/14/14 40.0 0.0 X 95955 0 2686 KEVIN SLY VP BD 40.0 0.0 X 278588 0 34869 LEWIS SCHRAGER VP Scientific Affairs 40.0 0.0 X 234530 0 18461 KENNETH WALKER VP Vaccine Discovery 40.0 0.0 X 223925 0 29173 RITA KHANNA General Counsel 40.0 0.0 X 219543 0 17777 KARI STOEVER VP EA THRU 9/5/14 40.0 0.0 X 209476 0 18837 ERIC TSAO VP TECH OPS THRU 5/2/14 40.0 0.0 X 130084 0 13635 SADRITDIN ISHMUKHAMEDOV Director thru 11/21/14 40.0 0.0 X 210535 0 16639 ROBIN GOLDSTEIN Sr Dir PM 40.0 0.0 X 244699 0 20129 VICKY CARDENAS Dir ESFU thru 12/10/14 40.0 0.0 X 199489 0 20145 BARBARA SHEPHERD Dir Medical Writing 40.0 0.0 X 197575 0 21358 DAVID HOKEY Sr Dir Immunology & Animal St 40.0 0.0 X 184021 0 20396 3856857 0 348685 57 false true false Alexandria Real Estate 385 E Colorado Blvd Suite 299 PASADENA CA 91101 Landlord 3620245 Quintiles Ltd PROFESSIONAL SERVICES CENTRE LIVINGSTON 0 UK EH54 6GA Clinical 2826375 The University of Cape Town WERNER BEIT SOUTH BUILDING CAPE TOWN 0 SF EH54 6GA Clinical 1644279 Oregon Health Science University 2525 1st AVENEUE SUITE 120 PORTLAND OR 97207 Research 1578920 University of Pittsburgh Research 1128367 5 9809531 39795702 49605233 VACCINE MANUFACTURING 541900 2555918 34749 2521169 2555918 80488 80488 0 0 43134 -43134 0 -43134 -43134 6821 51 -51 6821 6770 6770 0 0 0 FOREIGN CURRENCY LOSS 900099 -100390 -100390 MISCELLANEOUS 900099 69 69 -100321 52104954 34818 2521169 -56266 0 0 500000 500000 0 3070552 2330076 740476 0 13253600 11790969 1462631 824088 682963 141125 1660983 1382879 278104 1066490 885071 181419 0 0 0 0 0 0 767738 767738 0 1726028 1351401 374627 0 0 3960723 3767733 192990 1570919 1357120 213799 0 389286 347029 42257 0 0 3620651 3400241 220410 308385 181422 126963 CONTRACT SERVICES 19161066 18126322 1034744 COLLABORATION AGREEMENTS 2278982 2268244 10738 LAB SUPPLIES AND MATERIALS 3206126 3204422 1704 TALENT MGMT AND RECRUITMENT 693586 424423 269163 58059203 52000315 6058888 0 300 300 17445284 22674221 11039623 2611227 46035 66333 0 0 0 0 0 0 0 396807 2358123 1950848 37752261 31960294 9142422 5791967 11176601 11232236 0 0 0 0 0 0 590947 660204 51799335 45384143 7127816 5916239 0 300000 381476 760409 0 0 0 0 0 0 0 0 0 0 1439955 1516430 8949247 8493078 X 7057549 5117193 35792539 31773872 0 0 42850088 36891065 51799335 45384143 -5954249 -4774 X false true X true true true X JOHNS HOPKINS BALTIMORE MD ST LOUIS ST LOUIS MO OREGON HEALTH PORTLAND OR NEW YORK UNIVERSITY NEW YORK NY ALBERT EINSTEIN COLLEGE OF MEDICINE NEW YORK NY UNIVERSITY OF ROCHESTER ROCHESTER NY MASSACHUSETTS GENERAL HOSPITAL CONCORD MA UNIVERSITY OF PITTSBURG PITTSBURG PA VACCINE RESEARCH CENTER AT NIH BETHESDA MD UNIVERSITY OF MASSACHUSETTS SCHOOL OF MEDICINE WORCESTER MA FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE WA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 18124057 14010763 4113294 0 165615 134536 31079 0 16307290 14904412 1402878 0 3155299 2910583 244716 5791967 0 DEFERRED RENT 1425672 DEFERRED 457 PLAN 90758 1516430 X 49560733 -4775 -26662 -31437 49592170 2512784 2512784 52104954 43227774 199922 199922 43027852 15031351 15031351 58059203 OTHER REVENUE ON BOOKS BUT NOT ON RETURN Income of Affiliate $ 3,036,825 Eliminations $ (3,063,487) --------------- Total $ (26,662) OTHER EXPENSES ON BOOKS BUT NOT ON RETURN Expenses of Affiliate $ 3,220,275 Eliminations $ (3,063,487) Reclassed Rental Expense $ 43,134 ----------------- $ 199,922 FIN 48 FOOTNOTE In accordance with authoritative guidance issued by the FASB, Aeras would recognize a tax liability when, despite management's belief that tax return positions are supportable, management believes that certain positions may not be fully sustained upon review by tax authorities. Liabilities for uncertain tax positions would be measured based upon the largest liability that is greater than 50% likely to be incurred on any settlement with taxing authorities. To the extent that the final tax outcome of these matters would differ from the liabilities recorded, such differences would be included in income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments also would be included in income tax expense. Management has evaluated Aeras' tax positions and has concluded that Aeras has taken no material uncertain tax positions that require adjustment to the consolidated financial statements to comply with the provisions of this guidance. Aeras is currently under no income tax examinations in any Federal, or state or local jurisdictions. Aeras is generally no longer subject to income tax examinations by the U.S. federal, state or local tax authorities for years ended December 31, 2010 and prior. OTHER REVENUE ON RETURN BUT NOT ON BOOKS Reclassed Rental Income $ 0 Reclassed Rental Expense $ (43,134) Income from Discontinued Operations $ 2,555,918 ------------------- $ 2,512,784 OTHER EXPENSES ON RETURN NOT ON BOOKS Loss from Discontinued Operations $ 15,031,351 ------------------- Total $ 15,031,351 true East Asia and the Pacific Program Services PRECLINICAL 744023 Europe Program Services PRECLINICAL 1158047 Sub-Saharan Africa Program Services CLINICAL 9096301 East Asia and the Pacific 1 3 Program Services PRECLINICAL 456434 Sub-Saharan Africa 1 21 Program Services CLINICAL 2448217 Europe Grant PRECLINICAL 500000 2 24 2 24 14403022 14403022 Europe (Including Iceland and Greenland) SEE PART V 500000 EFT CASH 1 false false true false false false FORM 990, SCHEDULE F, PART I, LINE 2 Aeras receives a request for support. Senior management reviews the request through the due diligence criteria approved by the Board and implemented by management. For example, the grantee must be a charity either under US law or under local law. Aeras may request governance documents from the organization, IRS determination letter (or local equivalent) indicating it is a charity, lists of executive staff and board members, and financial statements of the requestor. Upon management approval, funds are sent to the requesting organization. Copies of the request and payment are maintained at Aeras. FORM 990, SCHEDULE F, PART II, COLUMN (D) The purpose of the grant is to provide support to Clinical and Preclinical projects such as MTBVAC, HBHA VPM, UOX and ChAd. X X true true X X X X X false false false false false false false false false Thomas Evans President & CEO 488943 0 0 0 0 0 15600 0 20072 0 524615 0 0 ANN GINSBERG CMO 341987 0 4100 0 0 0 15600 0 5478 0 367165 0 0 JACQUELINE SHEA LUCAS COO 228873 0 0 0 0 0 7200 0 10647 0 246720 0 0 WENDY PENRY CHRO 206147 0 4000 0 0 0 12454 0 18766 0 241367 0 0 DANIEL REZNIKOV CFO FROM 5/1/14 154387 0 0 0 0 0 5769 0 2994 0 163150 0 0 KEVIN SLY VP BD 274888 0 3700 0 0 0 15600 0 19269 0 313457 0 0 LEWIS SCHRAGER VP Scientific Affairs 234530 0 0 0 0 0 13800 0 4661 0 252991 0 0 KENNETH WALKER VP Vaccine Discovery 220525 0 3400 0 0 0 13311 0 15862 0 253098 0 0 RITA KHANNA General Counsel 216743 0 2800 0 0 0 12688 0 5089 0 237320 0 0 SADRITDIN ISHMUKHAMEDOV Director thru 11/21/14 207135 0 3400 0 0 0 0 0 16639 0 227174 0 0 KARI STOEVER VP EA THRU 9/5/14 205476 0 4000 0 0 0 11224 0 7613 0 228313 0 0 ROBIN GOLDSTEIN Sr Dir PM 242099 0 2600 0 0 0 14511 0 5618 0 264828 0 0 VICKY CARDENAS Dir ESFU thru 12/10/14 196889 0 2600 0 0 0 10451 0 9694 0 219634 0 0 BARBARA SHEPHERD Dir Medical Writing 194675 0 2900 0 0 0 11485 0 9873 0 218933 0 0 DAVID HOKEY Sr Dir Immunology & Animal St 180621 0 3400 0 0 0 10708 0 9688 0 204417 0 0 FORM 990, PART VI, LINE 11B A draft version of the Form 990 is shared with the Board of Directors of Aeras and once approved it is filed with the IRS. FORM 990, PART VI, LINE 12C Aeras' policy is written to protect Aeras' interest when it is contemplating entering into a transaction or arrangement that might benefit the private interest of directors, committee members, officers, employees and retained consultants of Aeras. In connection with any actual or possible conflicts of interest, an interested person must disclose the existence of his or her interest and all material facts to the directors and members of the committee with board-delegated powers considering the proposed transaction or arrangement. After disclosure of all material facts and discussion with the person, the person shall leave the board or committee meeting while their determination of a conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. FORM 990, PART VI, LINE 15 Aeras has a Compensation Committee which determines the CEO compensation level based on his responsibilities, size of the organization, funding levels and organization objectives. Compensation is based on comparability data, is approved by independent Board members, and the process is documented in the Board minutes. Compensation for other officers is determined by the CEO, based on the officer's responsibilities, funding levels and organization objectives. compensation is based on comparability data and is shared with independent board members. FORM 990, PART VI, LINE 19 Governing documents, including Articles of Incorporation, Bylaws, Board minutes, Conflict of Interest policy and financial statements are available upon request. FORM 990, PART III, LINE 4D Aeras also works to build relationships that support its goal to develop TB vaccines through collaboration at the global and regional levels with multi-lateral organizations such as the European Union, the European Investment Bank, and the World Health Organization, among other TB researchers and vaccine developers, as well as with donors, advocates and policymakers who can help raise awareness and support for this work. Aeras' Scientific and External Affairs departments are critical to advancing these strategic partnerships to ensure global support. AERAS SOUTH AFRICA BLACKRIVER PARK 1ST FLR CAPE TOWN OBSERVATORY SF 7925 CLINICAL TR SF N/A N/A NA true AERAS HONG KONG UNIT 1618 16/F MIRAMAR TOWER KOWLOON HK Holding Company HK Aeras C Corp -5827 431937 1.00000 true Aeras Beijing Biological Tech Co Ltd Unit 1446 14F A Tower Pacific Beijing CH Consulting CH Aeras Hong Kong C Corp -211721 142221 1.00000 true false false false false false false false false false false false true false false false false false false Aeras South Africa M 2889359 Cash Aeras Beijing Biological Tech Co Ltd M 174128 Cash